Patient Square Capital LP Invests $434,000 in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Patient Square Capital LP bought a new position in Astria Therapeutics, Inc. (NASDAQ:ATXS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 39,422 shares of the biotechnology company’s stock, valued at approximately $434,000. Astria Therapeutics comprises 0.2% of Patient Square Capital LP’s portfolio, making the stock its 11th biggest holding. Patient Square Capital LP owned approximately 0.07% of Astria Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Quest Partners LLC lifted its holdings in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC bought a new position in Astria Therapeutics in the 3rd quarter valued at approximately $140,000. SG Americas Securities LLC bought a new position in Astria Therapeutics in the 3rd quarter valued at approximately $155,000. Price T Rowe Associates Inc. MD bought a new position in Astria Therapeutics in the 1st quarter valued at approximately $200,000. Finally, Hsbc Holdings PLC bought a new position in Astria Therapeutics in the 2nd quarter valued at approximately $171,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

Shares of Astria Therapeutics stock opened at $10.23 on Wednesday. Astria Therapeutics, Inc. has a 52-week low of $4.67 and a 52-week high of $16.90. The stock’s 50-day simple moving average is $11.02 and its 200 day simple moving average is $10.65. The stock has a market capitalization of $577.28 million, a P/E ratio of -4.89 and a beta of 0.67.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ATXS. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research report on Thursday, November 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.